Recursion Pharmaceuticals Inc.
Clinical trials sponsored by Recursion Pharmaceuticals Inc., explained in plain language.
-
Promising meningioma drug trial halted early – what we know
Disease control TerminatedThis study tested a drug called REC-2282 in people with a rare genetic condition (NF2) that causes brain tumors called meningiomas. The trial aimed to see if the drug could slow tumor growth. It was stopped early, but the results may still help researchers understand how to treat…
Phase: PHASE2, PHASE3 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 26, 2026 04:34 UTC
-
Promising c. diff drug trial halted early
Disease control TerminatedThis study tested a new medicine called REC-3964 in adults who had a C. diff infection and were at high risk for it coming back. The goal was to see if the drug could safely prevent another infection. Only 3 people took part before the study was stopped early.
Phase: PHASE2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Experimental cancer drug trial halted early – what happened?
Disease control TerminatedThis study tested an experimental drug called REC-4881 in 18 adults aged 55+ with advanced solid tumors that had changes in the AXIN1 or APC genes. The goal was to see if the drug could shrink tumors or slow their growth. The trial was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 20, 2026 11:53 UTC